A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : MTX

Search Conditions:
Search Keyword : MTX
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: MTX
Appearance Frequency: 9841 time(s)
Long forms: 124

Display Settings:
[Display Entries]
Long Form, 100 entries
    (Appearance freq, Descending)
Long Form, all entries
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
methotrexate
(9364 times)
Rheumatology
(1973 times)
RA (2188 times)
DHFR (382 times)
ALL (365 times)
1962 A comparative study of 5-fluorouracil (FU), 5-fluorodeoxyuridine (FUDR), and methotrexate (MTX)-progress report.
mitoxantrone
(127 times)
Pharmacology
(17 times)
MS (15 times)
DOX (10 times)
EDSS (6 times)
1984 Comparative microscopic study of cardiotoxicity and skin toxicity of anthracycline analogs.
maitotoxin
(105 times)
Pharmacology
(22 times)
CFP (3 times)
CTX (3 times)
L-VDCC (3 times)
1983 Contractile response of the rabbit aorta to maitotoxin, the most potent marine toxin.
methoxamine
(27 times)
Cardiology
(9 times)
eNOS (4 times)
NO (4 times)
PVL (4 times)
1985 Contribution of extracellular and intracellular calcium to the enhanced effect of an alpha-adrenergic agonist on amylase release from dispersed rat parotid cells.
Maurotoxin
(22 times)
Biochemistry
(15 times)
CTX (2 times)
Abu (1 time)
AgTx2 (1 time)
1997 Maurotoxin, a four disulfide bridge toxin from Scorpio maurus venom: purification, structure and action on potassium channels.
mosquitocidal toxin
(12 times)
Microbiology
(5 times)
ADPRTs (1 time)
btx (1 time)
EF-Tu (1 time)
1993 Cytotoxicity and ADP-ribosylating activity of the mosquitocidal toxin from Bacillus sphaericus SSII-1: possible roles of the 27- and 70-kilodalton peptides.
medical treatment with methotrexate
(9 times)
Gynecology
(3 times)
EP (4 times)
beta-hCG (1 time)
CL (1 time)
1999 Electrical stimulation prolongs the survival days of leukemic mice treated with methotrexate.
MTX group
(8 times)
Rheumatology
(7 times)
RA (5 times)
CrI (3 times)
RCTs (3 times)
2005 Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
maintenance therapy with methotrexate
(6 times)
Neoplasms
(4 times)
ALL (4 times)
6-MP (2 times)
BFM (1 time)
1976 [Pulmonary disease during mtx therapy in a.l.l. (author's transl)].
10  marine toxin maitotoxin
(6 times)
Biochemistry
(2 times)
CBF (1 time)
fMLP (1 time)
ROCC (1 time)
1983 Excitatory effect of the most potent marine toxin, maitotoxin, on the guinea-pig vas deferens.
11  methotrexate sodium
(6 times)
Skin Diseases
(2 times)
ADA (1 time)
DLQI (1 time)
FAE (1 time)
1978 Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis.
12  methotrexate treatment
(5 times)
Neurology
(1 time)
BA (2 times)
ADRs (1 time)
CIA (1 time)
1988 Natural and Chang liver cell cytotoxic studies of methotrexate-treated psoriatic patients with liver cirrhosis.
13  methotrexate alone
(4 times)
Rheumatology
(3 times)
ACR Pedi 75 (1 time)
BP (1 time)
CIMT (1 time)
2003 Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis.
14  methoxychlor
(4 times)
Biochemistry
(1 time)
DA (2 times)
ME (2 times)
5-HIAA (1 time)
2000 Possible estrogenic and/or antiandrogenic effects of methoxychlor on prolactin release in male rats.
15  high-dose-methotrexate
(3 times)
Radiology
(1 time)
CRT (1 time)
GC-MS (1 time)
MTXCL (1 time)
2002 Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
16  metaxin gene
(3 times)
Genetics
(1 time)
psGBA (1 time)
psMTX (1 time)
THBS3 (1 time)
1996 Structure and organization of the human metaxin gene (MTX) and pseudogene.
17  methohexital
(3 times)
Pharmacology
(1 time)
ED (1 time)
GABAAR (1 time)
GCS (1 time)
1986 Barbiturates block divalent cation action potentials in leech nociceptive cells.
18  methylxanthines
(3 times)
Chemistry
(1 time)
AC (1 time)
CAF (1 time)
GEE (1 time)
1986 Methylxanthine, alcohol-free diet and fibrocystic breast disease: a factorial clinical trial.
19  Mojave toxin
(3 times)
Molecular Biology
(2 times)
PLA2 (2 times)
nt (1 time)
1994 Genomic sequences encoding the acidic and basic subunits of Mojave toxin: unusually high sequence identity of non-coding regions.
20  polymer-methotrexate
(3 times)
Biocompatible Materials
(1 time)
3,4-DHBA (1 time)
FUdR (1 time)
HaCaT (1 time)
1987 Comparison of the inhibitory effects of hydroxyurea, 5-fluorodeoxyuridine, 3,4-dihydroxybenzylamine, and methotrexate on human squamous cell carcinoma.
21  5-methylthio-d-xylofuranose
(2 times)
Microbiology
(1 time)
LAM (2 times)
CI (1 time)
TB (1 time)
2018 A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis.
22  cytostatics--methotrexate
(2 times)
Medicine
(2 times)
DXR (2 times)
2000 Central action of some cytostatics--methotrexate (MTX) and doxorubicin (DXR). I. Long-term influence on the pain sensitivity and activity of brain dopaminergic system in mice.
23  drug-methotrexate
(2 times)
Neoplasms
(1 time)
CV (1 time)
HA (1 time)
LRET (1 time)
1985 [Radioimmunoassay of the antitumor drug--methotrexate (MTX)].
24  margatoxin
(2 times)
Reproductive Medicine
(1 time)
CC (1 time)
CTX (1 time)
EC (1 time)
2002 Potassium channel antagonists influence porcine granulosa cell proliferation, differentiation, and apoptosis.
25  matrix size
(2 times)
Radiology
(2 times)
MR (2 times)
CNR (1 time)
COC (1 time)
2002 Technical parameters affecting image characteristics in in vivo MR microscopy of the mouse.
26  maximal tolerated dose of methotrexate
(2 times)
Rheumatology
(2 times)
RA (2 times)
HAQ (1 time)
HAQ-DI (1 time)
2000 Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis.
27  mediating transfer of methotrexate
(2 times)
Pharmacology
(1 time)
PGE2 (1 time)
TCA (1 time)
1991 Evidence for the facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Basic properties and specificity for polyglutamate chain length.
28  metaxin
(2 times)
Genetics
(1 time)
GBA (2 times)
SCAMP37 (1 time)
THBS3 (1 time)
1997 Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease.
29  methoxetrate
(2 times)
Rheumatology
(2 times)
FACS (1 time)
IL (1 time)
JCA (1 time)
2002 Folinic acid antagonizes methotrexate-induced differentiation of monocyte progenitors.
30  Methylxanthines
(2 times)
Biochemistry
(1 time)
AD (1 time)
APP (1 time)
CAF (1 time)
2010 Caffeine, pentoxifylline and theophylline form stacking complexes with IQ-type heterocyclic aromatic amines.
31  modify toxicity of methotrexate
(2 times)
Rheumatic Diseases
(1 time)
MTHFR (2 times)
ATIC (1 time)
FPGS (1 time)
2006 Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia.
32  modulate the cytotoxicity of methotrexate
(2 times)
Neoplasms
(2 times)
DP (1 time)
HX (1 time)
1987 Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma.
33  MTX and calcium folinate (leucovorin) rescue therapy
(2 times)
Pharmacology
(1 time)
CL (1 time)
1999 Electrical stimulation prolongs the survival days of leukemic mice treated with methotrexate.
34  post-methotrexate
(2 times)
Dermatology
(1 time)
MRI (1 time)
1976 The relation of HL-A antigens to liver histology in methotrexate-treated psoriatics.
35  5-deoxy-5-methylthio-xylofuranose
(1 time)
Chemistry
(1 time)
LAM (1 time)
MSX (1 time)
2006 The 5-deoxy-5-methylthio-xylofuranose residue in mycobacterial lipoarabinomannan. absolute stereochemistry, linkage position, conformation, and immunomodulatory activity.
36  ABCG2-mediated transport of methotrexate
(1 time)
Biochemistry
(1 time)
ABC (1 time)
MDR (1 time)
TKI (1 time)
2009 Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
37  dendrimer-methotrexate
(1 time)
Biochemistry
(1 time)
CHO (1 time)
DCC (1 time)
DHFR (1 time)
2006 Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
38  disease-modifying therapy received methotrexate
(1 time)
Medicine
(1 time)
CS (1 time)
RA (1 time)
sTLR2 (1 time)
2020 ASSOCIATIONS BETWEEN EFFICACY OF THE THERAPY AND CIRCADIAN FLUCTUATIONS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH TOLL-LIKE RECEPTORS 2 EXPRESSION, AND NOS3 POLYMORPHISM IN FEMALES WITH RHEUMATOID ARTHRITIS.
39  dsDNA-methotrexate
(1 time)
Biophysics
(1 time)
AFM (1 time)
HOPG (1 time)
2011 In situ evaluation of anticancer drug methotrexate-DNA interaction using a DNA-electrochemical biosensor and AFM characterization.
40  etanercept-methotrexate
(1 time)
Rheumatology
(1 time)
DAS28 (1 time)
NRI (1 time)
2010 Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
41  glycan-methotrexate
(1 time)
Biochemistry
(1 time)
DHFR (1 time)
2006 High-mannose-type glycan modifications of dihydrofolate reductase using glycan-methotrexate conjugates.
42  insulin-methotrexate
(1 time)
Gastroenterology
(1 time)
--- 2004 Receptor binding characteristics and cytotoxicity of insulin-methotrexate.
43  lipid-PEG-methotrexate
(1 time)
Biomedical Engineering
(1 time)
CPT (1 time)
NRs (1 time)
NSs (1 time)
2015 Self-Targeted, Shape-Assisted, and Controlled-Release Self-Delivery Nanodrug for Synergistic Targeting/Anticancer Effect of Cytoplasm and Nucleus of Cancer Cells.
44  macrophages treated with methotrexate
(1 time)
Complementary Therapies
(1 time)
IL (1 time)
RANTES (1 time)
WPG (1 time)
2010 Wild Panax ginseng (Panax ginseng C.A. Meyer) protects against methotrexate-induced cell regression by enhancing the immune response in RAW 264.7 macrophages.
45  magnitude than methotrexate
(1 time)
Chemistry
(1 time)
--- 1991 Novel pyrrolo[2,3-d]pyrimidine antifolates: synthesis and antitumor activities.
46  major target of methotrexate
(1 time)
Hematology
(1 time)
ALL (1 time)
CCND1 (1 time)
DHFR (1 time)
2007 DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.
47  major toxic effects of methotrexate
(1 time)
Pediatrics
(1 time)
--- 1999 The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis.
48  marrow to specific methotrexate
(1 time)
Neoplasms
(1 time)
--- 1977 The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.
49  MBD therapy with methotrexate
(1 time)
Urology
(1 time)
PEP (1 time)
1992 [Repair of skin defect after extensive resection for penile cancer: report of two cases, and clinical observation of patients with penile cancer at Mie University hospital].
50  measure the effect of methotrexate
(1 time)
Rheumatology
(1 time)
IL-1beta (1 time)
mRNA (1 time)
RA (1 time)
1994 Mechanisms of methotrexate action in rheumatoid arthritis. Selective decrease in synovial collagenase gene expression.
51  mechanisms that underlie the methotrexate
(1 time)
Antineoplastic Agents
(1 time)
TJ (1 time)
ZO-1 (1 time)
2010 Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats.
52  mediating the majority of methotrexate
(1 time)
Biochemistry
(1 time)
--- 1995 Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells.
53  medical therapy combining multidose methotrexate
(1 time)
Medicine
(1 time)
CSP (1 time)
2015 Novel Medical Therapy of Cesarean Scar Pregnancy With a Viable Embryo Combining Multidose Methotrexate and Mifepristone: A Case Report.
54  medical treatment with intramuscular methotrexate
(1 time)
Medicine
(1 time)
EGFR (1 time)
hCG (1 time)
tEP (1 time)
2013 Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol.
55  medical treatment with systemic methotrexate
(1 time)
Gynecology
(1 time)
ECA (1 time)
2014 The efficacy of the systemic methotrexate treatment in caesarean scar ectopic pregnancy: A quantitative review of English literature.
56  medium-term effects of methotrexate
(1 time)
Pharmacology
(1 time)
--- 2000 Additive effect of indomethacin and methotrexate on suppression of growth in rats.
57  metabolic turnover of methotrexate
(1 time)
Biochemistry
(1 time)
--- 1992 Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds.
58  metaphylaxis
(1 time)
Therapeutics
(1 time)
BRD (1 time)
2008 Evaluation of on-arrival versus prompted metaphylaxis regimes using ceftiofur crystalline free acid for feedlot heifers at risk of developing bovine respiratory disease.
59  method to facilitate methotrexate
(1 time)
Pharmacology
(1 time)
--- 1988 Effects of combination of vasodilator drugs and hypertonic solutions on methotrexate distribution into the rat brain.
60  method to monitor methotrexate
(1 time)
Chemistry Techniques, Analytical
(1 time)
CE (1 time)
CSF (1 time)
DAMPA (1 time)
2010 Analysis of methotrexate and its eight metabolites in cerebrospinal fluid by solid-phase extraction and triple-stacking capillary electrophoresis.
61  methodology to calculate methotrexate
(1 time)
Drug Therapy
(1 time)
--- 1996 A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.
62  METHODS: In a randomised, double-blind, controlled trial, patients received placebo+MTX
(1 time)
Rheumatology
(1 time)
OCR (1 time)
RA (1 time)
2012 Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.
63  METHODS: The concentration of methotrexate
(1 time)
Complementary Therapies
(1 time)
BBB (1 time)
BCNU (1 time)
2001 Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
64  METHODS: The effects of maitotoxin
(1 time)
Physiology
(1 time)
EPPs (1 time)
2001 [Effects of maitotoxin on the transmission of neuromuscular junction in rats].
65  METHODS: The efficacy of methotrexate
(1 time)
Neoplasms
(1 time)
--- 2007 Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
66  methohexital sodium
(1 time)
Emergency Medicine
(1 time)
--- 1991 The efficacy and safety of methohexital in the emergency department.
67  Methortrexatum
(1 time)
Dentistry
(1 time)
5-FU (1 time)
E-ADM (1 time)
PYM (1 time)
2003 [Chemosensitivity testing of oral and maxillofacial cancer with biopsy specimens].
68  methotrexate administered
(1 time)
Rheumatology
(1 time)
EORA (1 time)
LDA (1 time)
YORA (1 time)
2021 Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity.
69  methotrexate formulations
(1 time)
Nanotechnology
(1 time)
AIA (1 time)
LDE (1 time)
2013 Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis.
70  methotrexate group
(1 time)
Cell Biology
(1 time)
VitB17 (2 times)
2020 Vitamin B17 Ameliorates Methotrexate-Induced Reproductive Toxicity, Oxidative Stress, and Testicular Injury in Male Rats.
71  methotrexate is correlated with the Ki
(1 time)
Biochemistry
(1 time)
--- 1990 Transfection of DHFR- and DHFR+ mammalian cells using methotrexate-resistant mutants of mouse dihydrofolate reductase.
72  methotrexate monotherapy
(1 time)
Rheumatic Diseases
(1 time)
ACRp (1 time)
CHAQ (1 time)
CHQ (1 time)
2019 Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
73  methotrexate tablets
(1 time)
Complementary Therapies
(1 time)
DD (1 time)
ESR (1 time)
Fbg (1 time)
2018 [Acupuncture combined with western medicine on rheumatoid arthritis and effects on blood stasis].
74  methotrexate-based regimen
(1 time)
Neoplasms
(1 time)
EI (1 time)
2019 Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
75  Methotrexate-loaded
(1 time)
Pharmacology
(1 time)
HA (1 time)
NPs (1 time)
PEI (1 time)
2021 M2 TAM-associated STAT3/NF-κB signalling suppression as major target of immunomodulatory therapy with PLGA-based nanocarriers and anti-PD-L1 in breast cancer.
76  methotrexate/week
(1 time)
Rheumatology
(1 time)
--- 1988 Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of a case and review of the literature.
77  Methoxamine hydrochloride
(1 time)
Biomedical Engineering
(1 time)
ASC (1 time)
HPLC (1 time)
LLOQ (1 time)
2007 Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride.
78  methoxsalen
(1 time)
Physiology
(1 time)
Ca (1 time)
CFTR (1 time)
2002 Methoxsalen stimulates electrogenic Cl- secretion in the mouse jejunum.
79  Methoxyflurane
(1 time)
Emergency Medicine
(1 time)
INF (1 time)
2010 Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service.
80  methylthio-d-xylose
(1 time)
Biochemistry
(1 time)
DP-MTX (1 time)
LAM (1 time)
2017 Biosynthesis of the Methylthioxylose Capping Motif of Lipoarabinomannan in Mycobacterium tuberculosis.
81  mg/kg. concentration-time profiles of methotrexate
(1 time)
Pharmacology
(1 time)
--- 1995 The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain.
82  micro-textured
(1 time)
CFU (1 time)
GI (1 time)
GII (1 time)
2019 The Effect of Er,Cr:YSGG and Diode Laser Applications on Dental Implant Surfaces Contaminated with Acinetobacter Baumannii and Pseudomonas Aeruginosa.
83  microencapsulation, the composite methotrexate
(1 time)
Nanotechnology
(1 time)
--- 2012 Formation of methotrexate-PLLA-PEG-PLLA composite microspheres by microencapsulation through a process of suspension-enhanced dispersion by supercritical CO2.
84  mini-methorexate
(1 time)
Hematology
(1 time)
allo-SCT (1 time)
AML/MDS (1 time)
AUC (1 time)
2010 Clofarabine fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
85  minimize toxicity of high-dose methotrexate
(1 time)
Biochemistry
(1 time)
--- 2012 Discordance between urine pH measured by dipstick and pH meter: implications for methotrexate administration protocols.
86  Mitoxanthrone
(1 time)
Cardiology
(1 time)
ECG (1 time)
LVEF (1 time)
MS (1 time)
2015 Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
87  mitoxantrone dihydrochloride
(1 time)
Biomedical Engineering
(1 time)
PSi (1 time)
2013 Engineering porous silicon nanostructures as tunable carriers for mitoxantrone dihydrochloride.
88  Mitoxantrone HCl
(1 time)
Biology
(1 time)
FA (1 time)
2015 Folic acid-conjugated TiO2-doped mesoporous carbonaceous nanocomposites loaded with Mitoxantrone HCl for chemo-photodynamic therapy.
89  mitoxantrone hydrochloride
(1 time)
Chemistry
(1 time)
BP NSs (1 time)
HA (1 time)
NIR (1 time)
2019 pH/near infrared dual-triggered drug delivery system based black phosphorus nanosheets for targeted cancer chemo-photothermal therapy.
90  Mixture 2-treated group, methotrexate
(1 time)
Complementary Therapies
(1 time)
CIA (1 time)
RA (1 time)
TNF-alpha (1 time)
2008 [Effects of Tongbi Mixture 2 on expressions of CD28 and CD152 and content of tumor necrosis factor-alpha in peripheral blood in rats with collagen-induced arthritis].
91  molecular target of methotrexate
(1 time)
Allergy and Immunology
(1 time)
--- 2005 Modulation of orphan nuclear receptor NURR1 expression by methotrexate in human inflammatory joint disease involves adenosine A2A receptor-mediated responses.
92  monocytostatic treatment trial with Methotrexat
(1 time)
Neoplasms
(1 time)
BLM (1 time)
1979 Combined regional chemotherapy and radiation therapy in the treatment of epidermoid carcinoma in the oro-facial region.
93  monotherapy was similar to the combination of ABA+methotrexate
(1 time)
Rheumatology
(1 time)
ABA (1 time)
NMA (1 time)
RCTs (1 time)
2020 Comparative efficacy and safety of current therapies for early rheumatoid arthritis: a systematic literature review and network meta-analysis.
94  monotherapy, ETN+methotrexate
(1 time)
Rheumatology
(1 time)
CDAI (1 time)
DMARD (1 time)
ETN (1 time)
2015 Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
95  monotherapy, tofacitinib with methotrexate
(1 time)
Rheumatology
(1 time)
CDAI (1 time)
MRI (1 time)
OMERACT (1 time)
2019 Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
96  more than a decade, methotrexate
(1 time)
Rheumatology
(1 time)
DM (1 time)
2005 The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids.
97  Moreover, the folate analogue methotrexate
(1 time)
Pharmacology
(1 time)
TPMT (1 time)
2020 Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism.
98  MTX (n = 129) or IV golimumab 2-4 mg/kg
(1 time)
Rheumatology
(1 time)
LTE (1 time)
RA (1 time)
s.c (1 time)
2011 Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
99  MTX after high-dose methotrexate
(1 time)
Antineoplastic Agents
(1 time)
CAVH (1 time)
CF (1 time)
CH (1 time)
1995 [Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure].
100  MTX and medium
(1 time)
Biochemistry
(1 time)
--- 1992 Methotrexate transport in the human intestine. Evidence for heterogeneity.